1 / 63

Blood coagulation and fibrinolysis

Blood coagulation and fibrinolysis. March 2006. Haemostasis. adhesion shape change activation and secretion aggregation interaction with coagulation factors . Drug classes. 1. Anticoagulants 2. Antiplatelet drugs 3. Thrombolytic Agents . Anticoagulants. Heparin.

huyen
Download Presentation

Blood coagulation and fibrinolysis

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Blood coagulation and fibrinolysis March 2006

  2. Haemostasis • adhesion • shape change • activation and secretion • aggregation • interaction with coagulation factors

  3. Drug classes 1. Anticoagulants 2. Antiplatelet drugs 3. Thrombolytic Agents

  4. Anticoagulants

  5. Heparin Glycosaminoglycan containing a mixture of sulfated mucopolysaccharides of various sizes - Unfractionated (5000-30000 Da) - Low molecular weight (LMWH) (1000-10000 Da)

  6. Mechanism of Action • Heparin : - enhances the action of Antithrombin III(AT-III) (plasma protease inhibitor) 1000 fold ↑ activity - antithrombin III inhibits clotting factor proteases, Thrombin (IIa), IXa, Xa, XIa and XIIa, by forming stable complexes - heparin binds to AT-III and causes a conformational change thereby activating AT-III • LMWH: - predominantly inhibit factor Xa • Heparins do not affect thrombin bound to fibrin or Xa bound to platelets

  7. Monitoring Therapy • APTT (APTTR) (Activated Partial Thromboplastin Time) Intrinsic pathway (heparin) • PT (INR) (Prothrombin Time) Extrinsic pathway (warfarin)

  8. Heparin - indications • Rapid onset of action & short half life • When immediate anticoagulation required • When quick reversal may be required • Prevention and treatment of venous thrombosis • Pulmonary embolism • Acute Coronary syndromes • Given intravenously or subcutaneously • Can be used in pregnant women

  9. Adverse effects • Increased bleeding 3% - antidote (protamine sulfate) • Heparin induced thrombocytopaenia - HITs 1% up to 3 days 5% >5 days - Can precipitate thrombosis • Osteoporosis with long term high-dose administration 3-6mths • Inhibit aldosterone synthesis – rarely causes ↑K+

  10. Unfractionated heparin • Unpredictable pharmacokinetics • Requires regular monitoring • Infusion • Higher incidence of HITs • Rebound ischaemia

  11. Low Mol Weight Heparins • Eg Enoxaparin; Tinzaparin • More predictable pharmacokinetics • Lower incidence of heparin-associated thrombocytopenia • Ease of administration s/c injection • No need for monitoring • Possible improvement in outcomes of acute coronary syndromes (Such a benefit was suggested with enoxaparin in TIMI 11B, ESSENCE, and EVET)

  12. Oral Anticoagulants Sweet Clover

  13. Coumarins Warfarin, Dicumarol • Mechanism of action: • Block the Vitamin K-dependent glutamate carboxylation of precursor clotting factors II, VII, IX and X • Also inhibits Proteins C & S • 8-12 hour delay in action because of T1/2 of clotting factors in plasma • recovery needs synthesis of new clotting factors • action is reversed with vitamin K

  14. Monitoring Therapy • PT (INR) (Prothrombin Time) Extrinsic pathway (warfarin) • APTT (APTTR) (Activated Partial Thromboplastin Time) Intrinsic pathway (heparin)

  15. Warfarin • Highly plasma protein bound • Metabolised by liver • Substrate of CYP450 enzymes CYP1A2 (minor), 2C8/9 (major), 2C19 (minor), 3A4 (minor); Inhibits CYP2C8/9 (moderate), 2C19 (weak) • Excreted in urine and stool

  16. Indications • Prophylaxis and treatment of • venous thrombosis • pulmonary embolism • thromboembolic disorders • atrial fibrillation with risk of embolism • prophylaxis of systemic embolism post MI (LV thrombus)

  17. Adverse effects • Bleeding (risk depends on both the INR and patient factors) • Contraindicated in pregnancy - teratogenic effects, crosses placenta risk foetal haemorrhage • Warfarin induced skin necrosis - paradoxical local thrombosis - increased in patients with protein C or S deficiency • "Purple toes syndrome," cholesterol microembolization • Hepatic dysfunction

  18. Precautions • Patient compliance - eg dementia • Patient’s bleeding risk - eg falls, chronic liver disease, alcoholism, past history • Dietary factors - eg malnutrition • Drug interactions

  19. Interactions • Pharmacokinetic - changes in the absorption, protein binding, and/or metabolism - metabolism/elimination via cytochrome P450 system (common) - displacement of warfarin from plasma protein-binding sites eg NSAIDs (less important) • Pharmacodynamic - alter the risk of bleeding or clotting by either effect on platelet aggregation or vitamin K catabolism

  20. CYP450 and Warfarin • CYP2C8/9 inducers↓ warfarin effect eg Carbamazepine, phenobarbital, phenytoin, rifampin • CYP2C8/9 inhibitors ↑ warfarin effect eg fluconazole, gemfibrozil, ibuprofen, ketoconazole, mefenamic acid, miconazole, nicardipine, pioglitazone, amiodarone, isoniazid, losartan, omeprazole, pantoprazole • CYP2C8/9 gene polymorphism

  21. Alcohol and Warfarin • Acute ethanol ingestion (binge drinking) decreases the metabolism of warfarin and increases PT/INR • Chronic daily ethanol use increases the metabolism of warfarin and decreases PT/INR

  22. Food and Warfarin • The anticoagulant effects of warfarin may be decreased if taken with foods rich in vitamin K eg liver, green tea and leafy green vegetables • Vitamin E may increase warfarin effect • Cranberry juice may increase warfarin effect

  23. Herbal/Nutraceuticals • Cranberry, fenugreek, ginkgo biloba, glucosamine, may enhance bleeding or increase warfarin's effect • Ginseng (American), coenzyme Q10, and St John's wort may decrease warfarin levels and effects

  24. Antibiotics and Warfarin • Cytochrome P450 High risk >75% - eg Erythromycin, Clarithromycin, Ciprofloxacin, Co-trimoxazole, Metronidazole, Ketoconazole, Fluconazole • Any broad-spectrum antibiotics can suppress production of vitamin K by the gut flora

  25. Management of elevated INR • INR <6 No significant bleeding - Reduce dose or hold the next dose until INR <5 • INR >6 and <8 No significant bleeding - Hold the next 1or 2 doses until INR <5 then resume lower dose • INR >8: No significant bleeding - Hold warfarin until INR <5 - Vitamin K orally 5-10 mg or 0.5mg iv if high risk for bleeding • Any INR elevation + Serious bleeding - Hold warfarin, give vitamin K (10 mg by slow I.V. infusion), and supplement with fresh plasma transfusion or prothrombin complex concentrate (factor X complex)

  26. Vitamin K and Warfarin • Note: Use of high doses of vitamin K (10-15mg) may cause resistance to warfarin for more than a week • Heparin or low molecular weight heparin can be given until the patient becomes responsive to warfarin

  27. Newer Anticoagulants

  28. Direct Thrombin Inhibitors • Eg Hirudin, a naturally occurring anticoagulant • Bind directly to thrombin's catalytic site rather than to antithrombin III • Inhibit clot-bound thrombin • Increased risk of major hemorrhage with hirudin • Possible role in HITs

  29. Ximelegatran • Oral direct thrombin inhibitor • Concerns re: hepatotoxicity • No antidote

  30. Antiplatelet agents

  31. Antiplatelet agents • Predominantly prevent arterial thrombosis • In acute setting of MI & ischaemic stroke • Secondary prevention of vascular events • Primary prevention when 10 yr risk >15% and BP controlled

  32. Antiplatelet drug targets • Prostaglandin synthesis • ADP binding • GPIIb/IIIa receptor • Cyclic AMP

  33. Antiplatelet agents Aspirin inhibits cyclo-oxygenase  thromboxane A2 synthesis inhibits both COX 1 and COX 2 irreversibly

  34. COX-1 vs COX-2 inhibitors

  35. Aspirin • Pros - Inexpensive Proven efficacy • Cons – Intolerance Limited potency

  36. Adverse effects • GI ulceration 6-31% • Haemorrhage • Bronchospasm • Interstitial nephritis, papillary necrosis, proteinuria, renal failure • Reye’s syndrome in children CI <16yrs • Dangerous in overdose

  37. Antiplatelet agents Theinopyridines eg Clopidogrel, Ticlopidine Block activation of platelets by reducing ADP activation of Gp IIb / IIIa receptor complex

  38. Clopidogrel • Alternative to aspirin First choice for aspirin intolerance • In addition to aspirin in context of Primary PCI Acute coronary syndromes Secondary prevention of MI but NOT stroke

  39. Adverse effects • GI upset • Bleeding • Blood dyscrasias

  40. Aspirin + Clopidogrel • significant increase in major (3.7 versus 2.7 percent for aspirin alone) and minor bleeding (5.1 versus 2.4 percent) •  bleeding risk with clopidogrel plus aspirin in patients who require coronary artery bypass graft surgery (CABG)

  41. Antiplatelet agents Glycoprotein IIb/IIIa inhibitors (eg abciximab, eptifibatide) – inhibit cross-bridging of platelets by fibrinogen –Fab fragment of monoclonal antibody

  42. GP IIb/IIIa inhibitorsfor ACS • Among patients undergoing PCI with stenting • Periprocedural administration of GP IIb/IIIa inhibitors improves outcomes in patients with a non-ST elevation ACS • No evidence for benefit in context of thrombolysis

  43. Glycoprotein IIb/IIIa inhibitors • Adverse effects Drug-induced thrombocytopaenia Bleeding Emergency CABG (abciximab-treated patients were more likely to require surgical reexploration for bleeding (12 versus 3 percent))

  44. Antiplatelet agents Dipyridamole Inhibits platelet activation : by inhibiting platelet phospho-diesterase activity, stimulating prostacyclin synthesis, and blocking adensoine uptake

  45. Dipyridamole • pyrimido-pyrimidine derivative • vasodilatory effects on coronary resistance vessels • increases intracellular platelet cAMP activating the enzyme adenylate cyclase, and inhibiting uptake of adenosine from vascular endothelium and erythrocytes • *even the usual oral doses of dipyridamole may enhance exercise-induced myocardial ischemia in patients with stable angina

More Related